22 May 2013
Keywords: nps, drug, osteoporosis, track, ph, ii/iii, pharmaceuticals
Article | 10 March 2003
NPS Pharmaceuticals has reported that preliminary results from a PhaseII/III trial of Preos, the firm's parathyroid hormone-based drug for
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 March 2003
21 May 2013
© 2013 thepharmaletter.com